We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Supercomputers Used to Create Synthetic, Germ-Fighting Compounds

By LabMedica International staff writers
Posted on 16 Apr 2009
Since studies indicate that bacteria have little or no ability to resist antimicrobial peptides, one of the most fascinating possibilities of this finding is the creation of new forms of antibiotics to fight bacteria that have become resistant or immune to conventional drugs. More...
Scientists are now utilizing supercomputers to design and create synthetic small organic molecules and polymers--easier to make than peptides--that have the same mechanism of action as host defense proteins and with similar germ-fighting ability.

Based on the success of this research, scientists from the University of Pennsylvania (Philadelphia, PA, USA) filed for several patents and spun off of a biotech company named PolyMedix, Inc. (Radnor, PA, USA) to investigate the possibilities for useful applications as both novel therapeutic antibiotic drugs and as antimicrobial polymers for biomaterials applications.

These investigational antibiotic agents are the first of their kind to directly address the serious medical problem of bacterial drug resistance. The host defense proteins work essentially differently from all other known antibiotics: they punch holes directly in bacterial cell membranes, via a biophysical instead of a biochemical mechanism of action, in ways that makes resistance unlikely to develop. Up to now, data from a phase I study demonstrate that the compound is safe, and well-tolerated single doses were achieved at levels suggesting a beneficial therapeutic index. Additional clinical development will continue for the initial indication for this drug as a treatment for pan-Staphylococcal infections.

Staphylococcus aureus colonizes, without infecting, up to 30% of the human population. With the superbug's ubiquity and ability to invade almost any environment, no place is considered a safe haven against this deadly bacteria. Drug-resistant bacterial infections are one of the most significant medical problems facing the global population. Once typically thought of as a cure-all, antibiotics were the initial line of defense. Unfortunately, bacteria are becoming resistant to antibiotics due to overuse. While antibiotics-resistant superbugs are indeed a terrifying medical development, these newer innovative therapies suggest they are not invulnerable.

Related Links:

University of Pennsylvania
PolyMedix



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image: At the MHH Institute of Human Genetics: Prof. Dr. Doris Steinemann, Dr. Bernardus Aldrige Allister and Prof. Dr Monika Golas (from left). (Image Credit: Karin Kaiser/MHH)

Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer

Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.